According to Accessnewswire's report on February 12, American pharmaceutical company CTT Pharmaceutical Holdings, Inc. has submitted a full proposal to the National Science Foundation (NSF) for its patented product, a fast-dissolving nicotine film.
CTT has passed the first round of screening, and the company, along with other shortlisted candidates, will need to submit complete funding proposals before multiple deadlines within the next year. CTT anticipates receiving a response to the project by the end of April. If accepted, CTT Pharma will receive government funding for extensive research and testing.
The CEO of CTT, Ryan Khouri, stated that...
"Being able to pass the first round of applications itself is a huge achievement, indicating that the NSF sees the potential value of our technology in the tobacco industry. Currently, there are no soluble, low-dose nicotine strips on the market because most oral products stay in the mouth for too long. CTT has also invited someone with extensive experience in NSF funding to join our team to help advance this NSF funding application."
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
